BioSpace News Archive

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Tesis Biosciences, the leader in targeted genetic sequencing, has developed a new test that identifies the genetic mutations that puts people in the greatest danger from the Covid-19 virus.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2023 ended March 31, 2023, a period in which a loss was incurred in the first quarter and profitability restored in Q2.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the quarter ended March 31, 2023.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that on May 9, 2023, the compensation committee of BridgeBio’s board of directors granted 12 new employees restricted stock units for an aggregate of 149,400 shares of the Company’s common stock.

Solid Biosciences Inc. today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

Matinas BioPharma (NYSE American: MTNB) announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time.